PBMWW
Psyence Biomedical Ltd.
—
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
None
$0.02
+$0.00 (+4.65%)
Price History
52-Week Range
Sign in to add PBMWW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -58.62% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | 1.73 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $0.02 |
| 52-Week Low | $0.02 |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | 13.2K |
Performance Analysis
NEUTRALPBMWW presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($0.02), which may indicate limited upside.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Sep 09, 2026 15:16 UTC
Back to Screener Export Report